Trial Profile
A Randomized Phase II Trial of Bevacizumab (Avastin) and Temsirolimus (Torisel) in Combination With Intravenous Vinorelbine and Cyclophosphamide in Patients With Recurrent/Refractory Rhabdomyosarcoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2019
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Temsirolimus (Primary) ; Cyclophosphamide; Vinorelbine
- Indications Rhabdomyosarcoma; Soft tissue sarcoma
- Focus Adverse reactions; Registrational; Therapeutic Use
- 16 Sep 2019 Results published in the Childrens Hospital Los Angeles Media Release.
- 16 Sep 2019 According to an Childrens Hospital Los Angeles Media release, results from this study were recently published in the Journal of Clinical Oncology
- 12 Sep 2019 Primary endpoint (Event Free Survival Probability- comparison between Bevacizumab and Temsirolimus containing regimens) has been met.